<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1970">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135520</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH B-2105-687-003</org_study_id>
    <nct_id>NCT05135520</nct_id>
  </id_info>
  <brief_title>Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Kidney Specimen</brief_title>
  <official_title>A Prospective Randomized Controlled Study of Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Kidney Specimen (STTELS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the outcomes of transvaginal natural orifice specimen&#xD;
      extraction (NOSE) in patients who are planning multiport laparoscopic surgery for resection&#xD;
      of kidney.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:&#xD;
&#xD;
      This is a prospective, randomized, single center trial. This clinical trial was approved by&#xD;
      the Institutional Review Boards.&#xD;
&#xD;
      Study process:&#xD;
&#xD;
      All patients gave informed written consent after being informed of the details of the study.&#xD;
      Subjects were randomized into either the experimental group (specimen removal through&#xD;
      posterior vagina fornix incision) or control groups (specimen removal through extended&#xD;
      abdominal incision). All participants underwent demographic and history taking, laboratory&#xD;
      tests, a gynecologic examination to determine whether specimen removal through vagina is&#xD;
      possible.&#xD;
&#xD;
      To evaluate cosmesis, patient satisfaction and quality of life VAS (Visual Analogue Scale),&#xD;
      SF-12 (Short Form-12) health survey, BIQ (Body Image Questionnaire) and POSAS (the Patient&#xD;
      and Observer Scar Assessment Scale) will be sent to the patients 6 months after the surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 29, 2021</start_date>
  <completion_date type="Anticipated">November 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Transvaginal specimen extraction vs Transabdominal specimen extraction</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient and Observer Scar Assessment Scale (POSAS)</measure>
    <time_frame>post-op 1 week</time_frame>
    <description>Cosmetic outcomes of scar assessed by Patient and Observer Scar Assessment Scale (POSAS) 1 week and 8 weeks after surgery. The POSAS is the international validated scar assessment questionnaire that measures quality of the scar from the perspective of both patient and observer.&#xD;
observer scar assessment scale (OSAS): good (1) - bad (10)&#xD;
- vascularization/ pigmentation/ thickness/ relief/ pliability&#xD;
patient scar assessment scale (PSAS): No (1) - Yes (10)&#xD;
Is the scar painful?&#xD;
Is the scar itching?&#xD;
Is the scar color different from the color of your normal skin?&#xD;
Is the stiffness of the scar different from the color of your normal skin?&#xD;
Is the thickness of the scar different from the color of your normal skin?&#xD;
Is the scar more irregular than your normal skin?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient and Observer Scar Assessment Scale (POSAS)</measure>
    <time_frame>post-op 8 weeks</time_frame>
    <description>Cosmetic outcomes of scar assessed by Patient and Observer Scar Assessment Scale (POSAS) 1 week and 8 weeks after surgery. The POSAS is the international validated scar assessment questionnaire that measures quality of the scar from the perspective of both patient and observer.&#xD;
observer scar assessment scale (OSAS): good (1) - bad (10)&#xD;
- vascularization/ pigmentation/ thickness/ relief/ pliability&#xD;
patient scar assessment scale (PSAS): No (1) - Yes (10)&#xD;
Is the scar painful?&#xD;
Is the scar itching?&#xD;
Is the scar color different from the color of your normal skin?&#xD;
Is the stiffness of the scar different from the color of your normal skin?&#xD;
Is the thickness of the scar different from the color of your normal skin?&#xD;
Is the scar more irregular than your normal skin?</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaginal wound assessment</measure>
    <time_frame>post-op 1 week</time_frame>
    <description>assessment scale: No (0) - Yes (3) Vaginal bleeding Vaginal discharge Vaginal wound pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal wound assessment</measure>
    <time_frame>post-op 8 weeks</time_frame>
    <description>assessment scale: No (0) - Yes (3) Vaginal bleeding Vaginal discharge Vaginal wound pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-op pain assessment</measure>
    <time_frame>post-op 2hrs</time_frame>
    <description>Pain assessment with Visual analogue scale: No pain (0) - Worst pain (10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-op pain assessment</measure>
    <time_frame>post-op 6hrs</time_frame>
    <description>Pain assessment with Visual analogue scale: No pain (0) - Worst pain (10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-op pain assessment</measure>
    <time_frame>post-op 24hrs</time_frame>
    <description>Pain assessment with Visual analogue scale: No pain (0) - Worst pain (10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-op pain assessment</measure>
    <time_frame>post-op 48hrs</time_frame>
    <description>Pain assessment with Visual analogue scale: No pain (0) - Worst pain (10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index (FSFI) questionnaire</measure>
    <time_frame>post-op 5 months</time_frame>
    <description>Assessment Domain: Desire/ Arousal/ Lubrication/ Orgasm/ Satisfaction/ Pain Full scale score range: min 2.0 - max 36</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Urologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Transabdominal specimen extraction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The outcomes of transabdominal specimen extraction in a classic way in patients who underwent multiport laparoscopic surgery for resection of kidney</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transvaginal natural orifice specimen extraction (NOSE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The outcomes of transvaginal natural orifice specimen extraction (NOSE) in patients who underwent multiport laparoscopic surgery for resection of kidney</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transvaginal natural orifice specimen extraction (NOSE)</intervention_name>
    <description>Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney or bladder will undergo Transvaginal NOSE</description>
    <arm_group_label>Transvaginal natural orifice specimen extraction (NOSE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transabdominal specimen extraction</intervention_name>
    <description>Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney or bladder will undergo transabdominal specimen extraction with incision elongation</description>
    <arm_group_label>Transabdominal specimen extraction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are accessible with vaginal approach&#xD;
&#xD;
          -  Patients scheduled for laparoscopic resection of kidney for benign or malignant&#xD;
             diseases&#xD;
&#xD;
          -  Patients with normal cervical cancer screening tests within the last 3 years except&#xD;
             inflammatory findings&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients without sexual intercourse&#xD;
&#xD;
          -  Patients who are considered unable to remove specimen through vagina due to narrow&#xD;
             introitus in gynecological examination&#xD;
&#xD;
          -  Patients who are expected to have severe adhesion due to deep infiltrative&#xD;
             endometriosis or previous pelvic surgery history&#xD;
&#xD;
          -  Patients with abnormal cervical cancer screening tests&#xD;
&#xD;
          -  Patients scheduled to perform concomitant hysterectomy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>natural orifice specimen extraction</keyword>
  <keyword>laparoscopic surgery</keyword>
  <keyword>transvaginal</keyword>
  <keyword>female</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 20, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT05135520/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

